Abpro Holdings (ABPO) Non-Current Debt (2023 - 2026)
Abpro Holdings' (ABPO) quarterly Non-Current Debt came in at $147000.0 in Q1 2026, down 99.02% YoY from $15.0 million in Q1 2025, and up 568.18% on a QoQ basis from $22000.0 in Q4 2025.
Abpro Holdings (ABPO) Non-Current Debt (2023 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 4 years of Non-Current Debt data on file, last reported at $147000.0 in Q1 2026.
- Quarterly Non-Current Debt fell 99.02% year-over-year to $147000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $147000.0 (down 99.02% YoY) and the FY2025 annual result came in at $22000.0, down 85.03% from the prior year.
- Non-Current Debt improved to $147000.0 in Q1 2026, from $22000.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $15.0 million in Q1 2025 to a low of $22000.0 in Q4 2025.
- A 4-year average of $3.9 million and a median of $160000.0 in 2024 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2025 — Non-Current Debt soared 9275.0% — and 2026, when it sank 99.02%.
- Tracing ABPO's Non-Current Debt over 4 years: stood at $300000.0 in 2023, then plunged by 51.0% to $147000.0 in 2024, then slumped by 85.03% to $22000.0 in 2025, then surged by 568.18% to $147000.0 in 2026.
- The last three Non-Current Debt figures came in at $147000.0 (Q1 2026), $22000.0 (Q4 2025), and $15.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 8.96 Bn |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | 124,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147,000.00 |
| Dec 31, 2025 | 22,000.00 |
| Jun 30, 2025 | 15.00 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Dec 31, 2024 | 147,000.00 |
| Jun 30, 2024 | 160,000.00 |
| Mar 31, 2024 | 160,000.00 |
| Dec 31, 2023 | 300,000.00 |